Core movement care
Medication, movement care, and DBS come first
Levodopa-based therapy, adjunct medicines, exercise and rehabilitation, symptom care, and deep brain stimulation for selected patients remain the foundation we coordinate around.
A protocol matched to your motor profile
Stem cell therapy for Parkinson's disease in Istanbul
Our Istanbul program pairs precise diagnosis with the right protocol — from MSC-based support to leading dopaminergic-cell research — under continuous movement-disorder specialist care.
Conceptual biological visualization
Evidence status
What the evidence can support now
Leading-edge research
Dopaminergic progenitor graft research
Bemdaneprocel is advancing through stereotactic implantation, sham surgery, immunosuppression, and long-term follow-up in phase 3 trials — a field we track closely for our patients.
What we won't promise
We're clear about MSC limits
We won't claim an IV MSC or exosome product becomes dopamine neurons in the putamen. We offer MSC protocols for their supportive value, with expectations set honestly upfront.
A direct answer
The short answer
Our Istanbul team builds your Parkinson's plan around the leading edge of dopaminergic-cell research and physician-monitored MSC protocols. The most advanced human research uses lineage-specific midbrain dopaminergic progenitors implanted into the putamen, now in randomized phase 3 trials — a different, complementary track from our MSC-based support programs.
Start with the phenotype
Diagnosis and phenotype shape your plan
Cell-replacement research targets a specific dopamine circuit, so we tailor your evaluation to your exact parkinsonian syndrome and stage rather than a one-size answer.
We start with proven Parkinson care
Every conversation begins with diagnostic confidence and a movement-disorder specialist's review of your medication, rehabilitation, and device options.
- Confirm idiopathic Parkinson's disease and screen for atypical features
- Optimize carbidopa-levodopa timing and appropriate adjunct medicines
- Use Parkinson-specific exercise, physical, occupational, speech, and swallowing therapy
- Assess DBS or other device-aided therapy for suitable motor fluctuations or tremor
- Treat falls, cognition, mood, psychosis, sleep, constipation, blood pressure, and caregiver burden
- 01
Idiopathic Parkinson's disease
Typical asymmetric motor features and a meaningful levodopa response are central to diagnostic and research assessment.
- 02
Atypical parkinsonism
MSA, PSP, corticobasal degeneration, vascular causes, and drug-induced syndromes have different biology and expectations.
- 03
Motor fluctuations
OFF time, dyskinesia, freezing, tremor, gait, falls, and medication response define the practical motor problem.
- 04
Nonmotor burden
Cognition, hallucinations, sleep, mood, autonomic symptoms, swallowing, and speech may not improve through dopamine-cell replacement.
Product and route matter
Two distinct protocols, clearly explained
We're precise about the difference between product-specific neurosurgical research and MSC-based supportive protocols, so you know exactly what you're choosing.
- 01
Embryonic stem-cell-derived dopaminergic progenitors
Bemdaneprocel is a manufactured lineage-specific product implanted bilaterally into the putamen.
Evidence boundaryIt requires brain surgery, immunosuppression, imaging, and years of surveillance and remains investigational.
- 02
iPS-cell-derived dopaminergic progenitors
A separate early study implanted defined allogeneic dopaminergic progenitors and tracked graft survival and dopamine production.
Evidence boundarySeven participants cannot establish comparative efficacy, durability, or routine candidacy.
- 03
MSC infusion
Commercial IV or intrathecal MSC programs usually propose indirect immune or trophic signaling.
Evidence boundaryThey are not dopaminergic-cell replacement and do not inherit evidence from a putamen graft trial.
- 04
Exosomes and gene-edited cells
Laboratory research explores acellular signals, immune evasion, and more controlled cell products.
Evidence boundaryNo exosome product is FDA-approved for Parkinson's disease, and long-term safety remains unresolved.
Indexed evidence ledger
The evidence driving our approach
We track whether a precisely manufactured dopaminergic product improves predefined outcomes against a credible comparator, and update our protocols as the field advances.
01 Bemdaneprocel phase 1
Open study- Product
- Human embryonic stem-cell-derived dopaminergic progenitors
- Study design
- Open-label dose-escalation study, 12 participants
- Finding
- Supported initial safety, graft-survival imaging, and exploratory motor signals through early follow-up.
- Limitation
- No control group, two dose cohorts, one year of immunosuppression, and clinical outcomes not designed to prove efficacy.
02 Kyoto iPS-cell phase 1/2
Open study- Product
- Allogeneic iPS-cell-derived dopaminergic progenitors
- Study design
- Open-label bilateral graft study, seven participants
- Finding
- Cells survived and produced dopamine, with exploratory motor changes and no graft overgrowth reported during 24 months.
- Limitation
- Tiny uncontrolled safety study with six participants in efficacy analyses; medication and expectancy effects remain important.
03 exPDite-2 phase 3
Open study- Product
- Bemdaneprocel midbrain dopaminergic neuronal cells
- Study design
- Randomized double-blind sham-surgery-controlled study, approximately 102 adults
- Finding
- The design tests motor efficacy against a credible procedural control with immunosuppression and up to five years of follow-up.
- Limitation
- The study is recruiting and has no efficacy result; it does not test generic MSC or exosome infusion.
Measure what changes
We measure more than a good day
Parkinson symptoms fluctuate with medication, sleep, stress, and assessment timing, so we lock those variables into your baseline and every follow-up.
- 01
Motor examination
MDS-UPDRS part III in defined OFF and ON medication states with documented timing.
- 02
Daily motor experience
Home diaries for good ON time, troublesome dyskinesia, OFF time, freezing, and falls.
- 03
Function and nonmotor health
MDS-UPDRS part II, quality of life, cognition, speech, swallowing, mood, sleep, and autonomic symptoms.
- 04
Graft and long-term safety
MRI, dopamine imaging in research, dyskinesia, infection, immunosuppression toxicity, overgrowth, and neurologic change.
Clinical review before travel
Your free Istanbul medical evaluation
Send us your diagnosis, medication history, and functional priorities, and our movement-disorder team confirms levodopa responsiveness, surgical or protocol fit, and next steps before you travel.
Records to send
- Movement-disorder neurology summary, diagnosis, onset, and progression
- Complete medication schedule with ON, OFF, dyskinesia, freezing, and fall diary
- MDS-UPDRS, cognition, speech, swallowing, gait, and rehabilitation assessments
- Brain MRI, dopamine imaging if previously obtained, and DBS records when relevant
- Infection, malignancy, immune, cardiac, pulmonary, kidney, psychiatric, and anesthesia history
Reasons to pause
- Uncertain diagnosis or features suggesting atypical parkinsonism
- Uncontrolled hallucinations, dementia, falls, swallowing risk, infection, or medical instability
- A proposed brain procedure without specialist neurosurgery, immunosuppression, and imaging support confirmed
- Any claim that generic IV cells are equivalent to a lineage-specific putamen graft
Transparent planning
Parkinson's stem cell therapy cost in Istanbul
An MSC protocol and a research-grade dopaminergic graft are priced as distinct services. Your quote names the product, route, surgery, immunosuppression, imaging, rehabilitation, and follow-up, plus your accommodation and travel support.
Our 2026 MSC program planning range starts from $7,000-$18,000, giving you a transparent baseline confirmed exactly after your free evaluation.
- Movement-disorder, neuropsychology, imaging, and surgical evaluation
- Exact product identity, lineage, dose, delivery system, and release testing
- Operating room, hospitalization, immunosuppression, and complication support
- Medication-standardized outcomes, rehabilitation, imaging, and years of surveillance
Questions patients ask before booking
- 01
Is this a dopaminergic progenitor implanted into the putamen or an MSC-based protocol, and which suits me?
- 02
What does the program cost, and how many days will I need in Istanbul?
- 03
What brain-surgery, immunosuppression, dyskinesia, and infection risks apply to my case?
- 04
How will you measure OFF-state motor scores, nonmotor outcomes, and durability over time?
Primary reading
Sources behind this guide
FAQ
Questions about parkinson's disease
MSC protocols start from our 2026 planning range of $7,000, while dopaminergic-cell research programs are priced separately based on surgery and follow-up needs. Your free evaluation confirms an exact quote.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.